At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of RAD001 Plus Bevacizumab in the Treatment of Patients With Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Everolimus for Metastatic Melanoma. Completed, enrolled 57 participants across 15 sites.
Detailed Summary
This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesUnited States
CollaboratorsGenentech, Inc., Novartis
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionOct 2010
Study CompletionOct 2011
TodayJul 2026
First PostedJan 11, 2008
Enrollment StartJan 1, 2008
Primary CompletionOct 1, 2010
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.5 years ago
Interventions
Bevacizumabdrug
15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
Everolimusdrug
10 mg by mouth daily